Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 2/20 | 0.36 |
| ▸ | LMNA | P02545 | 5/20 | 0.34 |
| ▸ | AR | P10275 | 3/20 | 0.34 |
| ▸ | HTR2A | P28223 | 2/20 | 0.32 |
| ▸ | HTR2C | P28335 | 2/20 | 0.32 |
| ▸ | HTR2B | P41595 | 2/20 | 0.32 |
| ▸ | MEN1 | O00255 | 4/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.32 |
| ▸ | ALOX12 | P18054 | 3/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 5/20 | 0.31 |
| ▸ | THRB | P10828 | 1/20 | 0.31 |
| ▸ | HTT | P42858 | 3/20 | 0.31 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.31 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.31 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.31 |
| ▸ | PPARG | P37231 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12749947 | 0.79 | CYP3A4 (0.45) | CYP3A4LMNAMEN1ALDH1A1KMT2A | |
| SCHEMBL4420868 | 0.75 | HTR2A (0.35) | ARHTR2AHTR2CHTR2B | |
| SCHEMBL12749861 | 0.75 | CA2 (0.42) | CYP3A4LMNAMEN1ALDH1A1KMT2A | |
| SCHEMBL12749952 | 0.75 | THRB (0.45) | CYP3A4THRB | |
| SCHEMBL12749869 | 0.74 | CYP3A4 (0.43) | CYP3A4HTR2AHTR2CHTR2BMEN1 | |
| SCHEMBL12749983 | 0.74 | ALDH1A1 (0.48) | CYP3A4LMNAMEN1ALDH1A1KMT2A | |
| SCHEMBL9798590 | 0.73 | SMN1; SMN2 (0.47) | CYP3A4LMNAALDH1A1SMN1; SMN2MAPT | |
| SCHEMBL12749956 | 0.72 | SLC2A1 (0.46) | CYP3A4HTR2CMEN1ALDH1A1KMT2A | |
| SCHEMBL12749977 | 0.71 | ALDH1A1 (0.42) | CYP3A4LMNAMEN1ALDH1A1KMT2A | |
| SCHEMBL10064898 | 0.70 | CYP3A4 (0.39) | CYP3A4LMNAHTR2AMEN1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7915258-B2 | Substituted 2,5-dihydro-3H-pyrazolo[4,3-C]pyridazin-3-one derivatives, preparation thereof and therapeutic use of the same | SANOFI-AVENTIS (FR) | 2011-03-29 | — | — | US | disclosed |
| US-7915258-B2 | Substituted 2,5-dihydro-3H-pyrazolo[4,3-C]pyridazin-3-one derivatives, preparation thereof and therapeutic use of the same | SANOFI-AVENTIS (FR) | 2011-03-29 | — | — | US | disclosed |
| US-20090281107-A1 | SUBSTITUTED 2,5-DIHYDRO-3H-PYRAZOLO[4,3-C]PYRIDAZIN-3-ONE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE OF THE SAME | SANOFI-AVENTIS (FR) | 2009-11-12 | — | — | US | disclosed |
| US-20090281107-A1 | SUBSTITUTED 2,5-DIHYDRO-3H-PYRAZOLO[4,3-C]PYRIDAZIN-3-ONE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE OF THE SAME | SANOFI-AVENTIS (FR) | 2009-11-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090281107-A1 | SUBSTITUTED 2,5-DIHYDRO-3H-PYRAZOLO[4,3-C]PYRIDAZIN-3-ONE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE OF THE SAME | DHFR, DPYD, QDPR | CYP3A4 123/4885LMNA 1357/4885AR 1671/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.